Skip to main content

MAIA Biotechnology, Inc.

corporate_fare Company Profile

MAIA Biotechnology, Inc.

MAIA·NYSE·Life Sciences·CIK 0001878313

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. Its lead asset is ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine), an investigational drug candidate with a dual mechanism of action incorporating telomere targeting and immunogenicity. In July 2022, the first patient was administered ateganosine in the company's Phase 2 human trial (THIO-101) in Australia. In December 2022, regulatory authorities in three European countries—Hungary, Poland, and Bulgaria—approved implementation of THIO-101, a Phase 2 clinical trial evaluating ateganosine in patients with Non-Small Cell Lung Cancer (NSCLC). In the trial, patients with advanced NSCLC are treated first with ateganosine followed a few days later by the immune checkpoint inhibitor Libtayo® (cemiplimab), manufactured and commercialized by Regeneron. Cemiplimab is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells and has been approved in the United States and the rest of the world for multiple cancer indications, including NSCLC. In February 2021, MAIA signed a clinical supply agreement with Regeneron to receive cemiplimab at no cost, representing a significant cost-savings for the study. In return, MAIA granted Regeneron exclusive development rights in combination with PD-1 inhibitors for NSCLC for the study period. In July 2025, MAIA initiated an expansion of the THIO-101 trial focused on third-line NSCLC patients who are resistant to checkpoint inhibitors and chemotherapy. The expansion will enroll up to 48 patients across two arms: Arm 1, continuing evaluation of ateganosine sequenced with Libtayo® (cemiplimab); and Arm 2, evaluating ateganosine as a monotherapy to further gain experience of ateganosine in the contribution of components.

MAIA Biotechnology, Inc. (NYSE:MAIA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 3 items for MAIA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-17, rated 7/10. Across its 3 most recent items scored 7 or higher, the top rating is 8/10, with 1 rated 8 or above. Recent SEC coverage for MAIA spans 4, 8-K, 10-Q.

Recent high-impact activity:

  • CEO Vlad Vitoc Buys 100,000 MAIA Shares for $100,000 on the Open Market
  • MAIA Reports 88% Disease Control Rate in Expanded Phase 2 THIO-101 Lung Cancer Study
  • MAIA Q3 Loss Narrows 19% to $7.2M; $21.3M Cash Alleviates Going-Concern Doubt

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$22.4M
Diluted EPS
-$0.70
Op. Cash Flow
-$18.84M
Operating Income
-$24.27M
Cash & Equivalents
$0
Debt / Equity
0.00×
Shares Outstanding
38.62M sh
Source: 10-K · filed 2026-03-23 · accession 0001493152-26-012088

Short Interest & Short Volume

9.02 days to cover

FINRA reported short interest of 2,453,516 shares in MAIA as of the October 30, 2026 settlement, a 2.8% decrease from the prior period — about 9.0 days to cover at its recent average daily volume. On November 19, 2026, 54.7% of MAIA volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,453,516 shares as of October 30, 2026
Change vs prior period▼ 2.8%
Days to cover9.02 at avg daily volume of 271,949
Daily short volume (FINRA facilities)54.7% of 660,871 shares on November 19, 2026
5-day average short volume53.3%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with M →
$1.11 -2.63% today
52-week range · as of 2026-11-17 $0.87 – $3.19
Market cap
$68.54M
Volume
115.6K (0.3× avg)
3-mo avg 431K
Live data · 2026-11-20 15:27 UTC · Market open

show_chartPrice Chart

Loading chart...

feed MAIA - Latest Insights

MAIA
Nov 17, 2026, 4:05 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $1.24
Real-time Price: $1.11 info
Change: -$0.130 (-10%) info
Market Cap: $68.543M info
MAIA
Nov 17, 2026, 9:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.02
Real-time Price: $1.11 info
Change: +$0.090 (+9%) info
Market Cap: $68.543M info
MAIA
Nov 09, 2026, 5:00 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.09
Real-time Price: $1.11 info
Change: +$0.020 (+2%) info
Market Cap: $68.543M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets